Trials / Completed
CompletedNCT00203138
Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
Patients who completed the study TVP-1012/232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinson's disease (PD). During this study the patient's safety, tolerability of rasagiline, and effectiveness of this therapy will be monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rasagiline mesylate |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-11-01
- Completion
- 2006-12-01
- First posted
- 2005-09-20
- Last updated
- 2011-04-12
Source: ClinicalTrials.gov record NCT00203138. Inclusion in this directory is not an endorsement.